PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
64.06
ESG score near Biotechnology median of 61.92. David Dodd would investigate if industry-standard ESG practices adequately address sector-specific risks.
59.39
Environmental score near Biotechnology median of 58.30. David Dodd would investigate if industry-standard environmental practices adequately address climate risks.
65.71
Social score near Biotechnology median of 64.11. David Dodd would investigate if industry-standard social practices adequately address stakeholder risks.
67.07
Governance score 1.1-1.2x Biotechnology median of 63.38. Philip Fisher would examine if superior governance practices support long-term value creation.